1 / 3

Lopes RD et al Lancet . 2012 Oct 1 .

ARISTOTLE: Stroke or systemic embolism according to different risk scores Secondary analysis of randomized trial. Number Of patients. Apixaban. Warfarin. HR (95% CI). P value. CHADS 2 score 1. CHADS 2 score 2. CHADS 2 score ≥ 3. CHA 2 DS 2 VASc score 1.

duante
Download Presentation

Lopes RD et al Lancet . 2012 Oct 1 .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ARISTOTLE: Strokeor systemicembolismaccording to different risk scoresSecondary analysis of randomized trial Number Of patients Apixaban Warfarin HR (95% CI) P value CHADS2 score 1 CHADS2 score 2 CHADS2 score ≥ 3 CHA2 DS2 VASc score 1 CHA2 DS2 VASc score 2 12 CHA2 DS2 VASc score ≥3 HAS-BLED Score 0-1 HAS-BLED Score 2 HAS-BLED Score ≥ 3 Overall Favoursapixaban Favourswarfarin LopesRD et al Lancet. 2012 Oct 1.

  2. ARISTOTLE: Major bleedingaccording to different risk scores Secondary analysis of randomized trial Number Of patients Apixaban Warfarin HR (95% CI) P value CHADS2 score 1 CHADS2 score 2 CHADS2 score ≥ 3 CHA2 DS2 VASc score 1 CHA2 DS2 VASc score 2 CHA2 DS2 VASc score ≥3 HAS-BLED Score 0-1 HAS-BLED Score 2 HAS-BLED Score ≥ 3 Overall Favoursapixaban Favourswarfarin LopesRD et al Lancet. 2012 Oct 1.

  3. ARISTOTLE: Intracranialbleedingaccording to different risk scores Secondary analysis of randomized trial Number Of patients Apixaban Warfarin HR (95% CI) P value CHADS2 score 1 CHADS2 score 2 CHADS2 score ≥ 3 CHA2 DS2 VASc score 1 CHA2 DS2 VASc score 2 CHA2 DS2 VASc score ≥3 HAS-BLED Score 0-1 HAS-BLED Score 2 HAS-BLED Score ≥ 3 Overall Favoursapixaban Favourswarfarin LopesRD et al Lancet. 2012 Oct 1.

More Related